Авторизація
|
Американський ринок терапії еректильної дисфункції (U.S. Erectile Dysfunction Therapies Market) Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year 2030. Although most cases are not reported, it is estimated that more than 30 million men affected in the United States (U.S).
Publisher: Medtech Insight
While ED is more common in men older than age 65, most men older than age 40 experience occasional difficulty; it is estimated that more than 50% of men older than age 40 report periodic episodes of ED. Despite the high number of cases, impotence is greatly undertreated, with only an estimated 15% of men seeking help from a physician due to the fact that they view the condition as personal or embarrassing. Since the launch of Pfizer’s oral drug Viagra (sildenafil) in 1998, there has been a considerable increase in public awareness of ED due to extensive marketing by leading drug manufacturers. As a result, the worldwide market for oral ED drugs has reached more than $4.2 billion. The U.S. market for ED therapies (defined in this report as including prescription ED drugs and penile implants) is expected to continue stable, moderate growth over the next 5 years. Valued at more than $1.9 billion in 2010, the market is expected to increase at a healthy compound annual rate of 5.1%, with sales reaching more than $2.5 billion in 2015. The U.S. ED therapies market is expected to benefit not only from continued strong demand but from highly positive demographic trends, including a large, growing ED population, strong advertising/marketing, emerging next-generation ED therapies, launch of several lower cost generic drugs, and the continued adoption of improved penile implant systems. This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging drugs, technology and opportunities. Covered topics in this report include erectile dysfunction drugs (existing and emerging oral and topical ED therapies), injectable and intraurethral agents, vacuum constriction devices, penile implants, and alternative treatments. TABLE OF CONTENTS EXECUTIVE SUMMARY i. Causes and Prevention ii. Diagnosis and Treatment a. Oral Drug Therapy b. Injectable and Intraurethral Drug Therapy c. Vacuum Pump Therapy d. Surgery/Penile Prosthesis Implantation iii. Erectile Dysfunction Therapies Market a. Drug Therapy b. Penile Implants iv. Methodology Exhibit ES-1: Erectile Dysfunction Therapies, Combined Market Forecast, 2010-2015 1. CLINICAL OVERVIEW OF ERECTILE DYSFUNCTION 1.1 Causes and Prevention 1.2 Diagnosis and Treatment 1.2.1 Oral Drug Therapy1.3 Emerging Treatments 2. ERECTILE DYSFUNCTION THERAPIES MARKET 2.1 Drug Therapy 2.1.1 Oral Agents2.2 Penile Implants 2.2.1 Inflatable Implants2.3 Vacuum Constriction Devices 2.3.1 Augusta Medical Systems2.4 Market Analysis 2.4.1 Drug Therapy MarketExhibit 2-1: Comparative Advantages and Disadvantages of Cialis, Levitra, STAXYN, and Viagra Exhibit 2-2: Erectile Function Improvement Using Low-Dose Once-Daily Cialis Exhibit 2-3: Erectile Function Improvement Using Low-Dose Once-Daily Cialisin Patients with Diabetes Exhibit 2-4: Erectile Function Improvement Using Low-Dose Once-Daily Cialis in Patients with Controlled Hypertension or Cardiovascular Disease Exhibit 2-5: Erection Confidence Improvement Using Low-Dose Once-Daily Cialis Exhibit 2-6: Common Adverse Events Associated with the Use of Low-Dose Once-Daily Cialis Exhibit 2-7: Erectile Function Improvement Using High-Dose Cialis Exhibit 2-8: Erectile Function Improvement Using High-Dose Cialis in Patients with Diabetes Exhibit 2-9: Erectile Function Improvement Using High-Dose Cialis in Patients with Controlled Hypertension or Cardiovascular Disease Exhibit 2-10: Erection Confidence Improvement Using High-Dose Cialis Exhibit 2-11: Common Adverse Events Associated with the Use of High-Dose Cialis Exhibit 2-12: STAXYN Orally Disintegrating Tablets Exhibit 2-13: Common Adverse Events Associated with the Use of STAXYN Exhibit 2-14: Erectile Function Improvement Using Viagra, Pivotal Efficacy Results Exhibit 2-15: Steps Involved in the Use of the MUSE Transurethral System Exhibit 2-16: 2011, Selected Emerging Erectile Dysfunction Products Exhibit 2-17: Benefits and Risks of Penile Implants Exhibit 2-18: Advantages and Disadvantages of the AMS 700 Inflatable Penile Implant Exhibit 2-19: The AMS 700 LGX Inflatable Penile Implant Exhibit 2-20: Advantages and Disadvantages of the AMS Ambicor Inflatable Penile Implant Exhibit 2-21: The Titan and Titan OTR Inflatable Penile Prostheses Exhibit 2-22: The Genesis Flexible Rod Implant Exhibit 2-23: The SOMAerectStf Vacuum Constriction Device Exhibit 2-24: The Vitality OTC Vacuum Constriction Device Exhibit 2-25: The Osbon ErecAid Vacuum Therapy System Exhibit 2-26: The BOSS 2000-3 and MVP 700 Vacuum Constriction Devices Exhibit 2-27: Erectile Dysfunction Drug Therapy, Patient Volumes Forecast, 2010-2015 Exhibit 2-28: Erectile Dysfunction Drug Therapy, Market Forecast, 2010-2015 Exhibit 2-29: 2010, Erectile Dysfunction Drug Therapy Market, Share by Supplier Exhibit 2-30: Penile Prosthesis Implantation, Procedure Volumes Forecast, 2010-2015 Exhibit 2-31: Penile Implants, Market Forecast, 2010-2015 Exhibit 2-32: 2010, Penile Implants Market, Share by Supplier 3. COMPANY PROFILES 3.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc. 3.2 Apricus Biosciences, Inc. 3.3 Bayer AG 3.4 Futura Medical PLC 3.5 Eli Lilly and Company 3.6 Pfizer, Inc. 3.7 Reckitt Benckiser PLC 3.8 Vivus, Inc. Перекладач: translate.google.com Американський ринок терапії еректильної дисфункції (U.S. Erectile Dysfunction Therapies Market) Американський ринок терапії доброякісної гіперплазії передміхурової залози мінімально інвазивним методом (U.S. Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market) Американський ринок терапії нетримання сечі мінімально інвазивним методом (U.S. Minimally Invasive Urinary Incontinence Therapy Systems Market) Американські ринки приладів загальної та ендоскопічної тазової хірургії (U.S. Markets for General and Pelvic Endoscopic Surgery Products) |
Новини
03.03.2023 Науково доведено: через смартфони ви можете старіти швидше
24.02.2023 Стимуляція спинного мозку відновлює постінсультну функцію рук 17.02.2023 Вчені відкрили здатність жирної їжі руйнувати мозок 10.02.2023 В Індії розробили неінвазивний тест, який використовує штучний інтелект для виявлення раку молочної залози 01.02.2023 Як спостереження за світанками та заходами сонця впливає на здоров'я – вчені 25.01.2023 Аналіз крові для ранньої діагностики хвороби Альцгеймера розробили вчені 18.01.2023 Людина з серцем свині. Пацієнту вперше пересадили серце тварини 11.01.2023 Вчені пояснили, чому оливкову олію варто пити ложками 21.11.2022 Вчені виявили ще одну причину високого ризику атеросклерозу 18.11.2022 Імплантована помпа доставила протиракові ліки у пухлини мозку 16.11.2022 Шум вночі може бути причиною безсоння та серцево-судинних захворювань 14.11.2022 ЩО ТРЕБА ЗНАТИ ПРО ЦУКРОВИЙ ДІАБЕТ: ТИПИ, СИМПТОМИ, УСКЛАДНЕННЯ 11.11.2022 Виявилося, в епідемії ожиріння винен лише один тип їжі 09.11.2022 Проказа: давня хвороба, здатна регенерувати органи 07.11.2022 "Чарівні гриби" можуть лікувати важку депресію 04.11.2022 Нове випробування пропонує переваги CV з EPA: RESPECT-EPA 02.11.2022 Майже 500 українських медиків завершили навчання з тактичної медицини 01.11.2022 Чи можна людям з діабетом пити алкоголь 31.10.2022 Знайдено овоч, здатний знизити цукор у крові відразу на 20% 28.10.2022 Людська печінка може працювати 100 років |